Navigation Links
Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig

PHILADELPHIA, Nov. 5, 2013 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NASDAQ: ARIA) stock between December 11, 2011 and October 31, 2013, inclusive. The investigation concerns whether Ariad and certain of its officers and/or directors disseminated materially false and misleading information to investors in violation of Sections 10(b), and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, promulgated thereunder.

Ariad describes itself as an oncology company, focused on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer, and other difficult-to-treat cancers.  On October 9, 2013, Ariad disclosed that Iclusig, a drug the FDA approved in December, 2012 as a last-line treatment for certain kinds of chronic myeloid leukemia, had shown higher than expected rates of serious health problems related to blood clots. Two days later, the U.S. Food and Drug Administration announced it was investigating severe and life-threatening blood clots and narrowing of blood vessels in current patients taking the medication. On October 18, 2013 the Company announced it had agreed to terminate a trial of the drug in newly-diagnosed patients because arterial thrombotic events were observed in patients taking Iclusig. On October 31, 2013, at the FDA's request, the Company disclosed that it was suspending sales of the drug.

Upon its October 31, 2013, disclosure that it was suspending sales of Iclusig, Ariad shares declined $2.07 per share or over 30%, to close at $4.70 per share. As of November 4, 2013, Ariad's stock was trading at $2.98 per share, down 85 percent from its trading value before October 8, 2013.

If you wish to discuss what rights you may have related to a loss in your investment in Ariad or you have any information on Ariad's representations about the Iclusig drug, please contact Eduardo Texidor Jr. at or, toll free, at 1-888-375-7600. For those investors inquiring via email, please include "Ariad" in the subject line, and, in the body of the email, the number of shares purchased and your mailing address and telephone number.

Since 1973, Cohen, Placitella & Roth, PC has been recognized as one of the premier trial law firms in the country. The firm has extensive experience in prosecuting securities litigation involving violations of the federal securities laws, state law derivative actions and mergers and acquisitions cases, representing institutional investors such as public pension plans and union pension funds as well as individual shareholders suffering substantial investment losses due to corporate misconduct. LexisNexis Martindale-Hubbell® annually reports Cohen, Placitella & Roth's peer rating-the highest AV® - "a testament to professional excellence." Since the inauguration of its "Best Law Firms"' edition in 2010, U.S. News and World Report has annually listed Cohen, Placitella & Roth as one of the top-tier class action law firms in the country.

Eduardo Texidor Jr.
Cohen, Placitella & Roth, PC
Toll free: 1-888-375-7600

SOURCE Cohen, Placitella & Roth, PC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
2. UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
3. Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence
4. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
7. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
8. Langland Collaboration with CISCRP to Show Participants How Their Words Can Impact a Clinical Trial
9. InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
10. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
11. French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
Breaking Medicine News(10 mins):